Report period | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
End date of the reporting period | |||||
Capitalization, $ | |||||
Capitalization, $ | |||||
Enterprise Value | |||||
Book Value | |||||
Shareholders Book Value | |||||
Current liabilities | |||||
Noncurrent liabilities | |||||
Total liabilities | |||||
Debt | |||||
Cash and cash equivalents | |||||
Net debt | |||||
Assets | |||||
Total ordinary shares | |||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
GRTX:US | Galera Therapeutics | Common share | - | US36338D1081 | $0.049 |
Company name | Galera Therapeutics |
---|---|
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 2 West Liberty Blvd Suite 110 Malvern, PA 19355 United States |
Mailing address | 2 West Liberty Blvd Suite 110 Malvern, PA 19355 United States |
Website | investors.galeratx.com |
Information disclosure | www.sec.gov |